Buy Humira (Adalimumab) — Online Prescription
Humira (adalimumab) is the injectable TNF-blocker biologic behind treatment for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and four other conditions. Here's how it works, how well it works for each condition, what the side effects really look like, the 10 FDA-approved biosimilars that now cost a fraction of the brand, and how to get it covered and filled.
Medically reviewed Medically reviewed by Sabrina Griswold, Pharm.D. — NPI 1821451063 · Last updated 2026-09-24
| Active ingredient | Adalimumab |
|---|---|
| Dosage form | Single-dose pen or prefilled syringe (40 mg/0.4 mL, 80 mg/0.8 mL; 10 mg and 20 mg syringes for children) |
| Administration route | Subcutaneous injection (under the skin) |
Indications: 1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inh…
Boxed warning: WARNING: SERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary…
Contraindications: 4 CONTRAINDICATIONS None. None ( 4 )
openFDA label data — Updated 2026-09-29Humira (adalimumab) is a prescription biologic injected under the skin, usually every other week, that blocks TNF-alpha, a key inflammatory signal. It's FDA-approved for 9 conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa. It works well for many patients but carries a boxed warning for serious infections and certain cancers, so you'll be tested for tuberculosis first. Brand Humira costs about $7,000 a month at cash price. There's no true generic, but 10 FDA-approved biosimilars exist, and unbranded versions cost pharmacies roughly 80–85% less. With insurance, most patients pay far less through copay cards or Medicare's 2026 out-of-pocket cap.
What Humira is and how it works
Humira is a monoclonal antibody: a lab-made protein designed to attach to one specific target in your body. Its target is tumor necrosis factor-alpha (TNF-α), a signaling protein your immune system uses to start inflammation. In rheumatoid arthritis, Crohn's disease, psoriasis and the other conditions Humira treats, TNF-α is overproduced. It keeps inflammation going when there is nothing to fight, and that inflammation damages joints, the gut lining or skin.
Two practical consequences follow from how it works:
- It's an injection, not a pill. Humira is a large protein that stomach acid would destroy, so it's injected under the skin with a pen or prefilled syringe, usually by the patient at home.
- It lowers some of your infection defenses. TNF-α is also how your body keeps infections like tuberculosis contained. That's the reason for the boxed warning and the TB test before you start.
- It's a long-term treatment, not a cure. Humira controls the disease while you take it. Stopping usually means symptoms return, so any change should be planned with your specialist.
What Humira is used for
Humira has nine FDA-approved uses. Insurers generally cover it for moderate-to-severe disease, often after a conventional treatment (such as methotrexate for rheumatoid arthritis) has been tried.
| Condition | Who it's approved for | What Humira does |
|---|---|---|
| Rheumatoid arthritis (RA) | Adults | Reduces symptoms, slows joint damage seen on X-ray, improves physical function; alone or with methotrexate |
| Juvenile idiopathic arthritis (polyarticular) | Children 2+ | Reduces signs and symptoms |
| Psoriatic arthritis (PsA) | Adults | Reduces symptoms, slows structural joint damage |
| Ankylosing spondylitis (AS) | Adults | Reduces back pain, stiffness and inflammation |
| Crohn's disease | Adults and children 6+ | Treats moderately to severely active disease |
| Ulcerative colitis (UC) | Adults and children 5+ | Treats moderately to severely active disease |
| Plaque psoriasis | Adults | For moderate-to-severe psoriasis when systemic therapy or phototherapy is appropriate |
| Hidradenitis suppurativa (HS) | Ages 12+ | Reduces painful nodules and abscesses |
| Uveitis (non-infectious) | Adults and children 2+ | Treats intermediate, posterior and panuveitis |
How well Humira works, by condition
Most drug pages just say Humira is "effective." The FDA label has the actual trial results. The chart below shows, for each condition, the share of patients who reached that trial's main goal on Humira compared with placebo.
Source: HUMIRA FDA prescribing information, section 14 (Clinical Studies). PASI 75 = at least 75% improvement in psoriasis severity score. ACR20 / ASAS20 = at least 20% improvement on standard arthritis / spondylitis scales. HiSCR = at least 50% fewer abscesses and inflammatory nodules.
Humira helps a lot in psoriasis and the arthritis conditions. In ulcerative colitis the benefit over placebo is real but modest: about 1 in 6 patients reached remission at week 8. That's why the label says to stop Humira in UC if there's no remission by week 8, and why newer drugs often come up in UC treatment decisions (see alternatives).
How long Humira takes to work
Humira is not a same-day treatment. Here's what the clinical trials show about timing. Your specialist will judge your own response against these milestones.
Earliest improvement. In the ankylosing spondylitis trial, benefit was first seen at week 2.
Crohn's induction check. After the 160 mg and 80 mg starting doses, remission was first measured at week 4.
Ulcerative colitis decision point. The label says to stop Humira if there's no clinical remission by day 57.
Main check for RA, AS and HS. Most of the benefit is visible by about 3 months. If you're not responding, your doctor may adjust the dose or switch drugs.
Psoriasis check. Skin clearance (PASI 75) was measured at 16 weeks.
Humira dosage by condition
Humira dosing depends on the condition. Several conditions start with higher loading doses to bring inflammation down faster. Adult dosing from the FDA label:
| Condition | Starting (loading) dose | Maintenance dose |
|---|---|---|
| Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | None | 40 mg every other week. In RA without methotrexate, 40 mg weekly or 80 mg every other week may be used. |
| Crohn's disease | 160 mg on day 1 (or split over days 1–2), then 80 mg on day 15 | 40 mg every other week from day 29 |
| Ulcerative colitis | 160 mg on day 1 (or split over days 1–2), then 80 mg on day 15 | 40 mg every other week from day 29. Stop if no remission by day 57. |
| Plaque psoriasis, adult uveitis | 80 mg once | 40 mg every other week, starting 1 week later |
| Hidradenitis suppurativa | 160 mg on day 1, then 80 mg on day 15 | 40 mg every week or 80 mg every other week from day 29 |
Children's doses (JIA, pediatric Crohn's, UC, uveitis and adolescent HS) are based on weight: 10 mg, 20 mg or 40 mg for arthritis and uveitis, with separate loading schedules for pediatric Crohn's and UC. Your child's specialist will set these. Adults on 80 mg every other week get about the same drug exposure as on 40 mg weekly.
Humira injection: how to use the pen and store it
Most patients inject Humira at home after one training session with a nurse, prescriber or pharmacist. These are the key steps for the pen, from the FDA-approved Instructions for Use:
- Take it out 15–30 minutes earlyLet the pen reach room temperature with both caps on. Don't warm it in a microwave or hot water. Check the expiration date, and check that the liquid is clear and colorless.
- Choose and clean a siteUse the front of your thigh, or your lower belly at least 2 inches from your navel. Use a different spot from last time, and avoid skin that's bruised, red, hard, scarred or has psoriasis plaques. Wipe with alcohol and let it dry.
- Squeeze and place at 90°Pinch the skin to make a raised area. Place the white needle sleeve straight against the skin (a 90-degree angle) so you can see the window.
- Press and holdPush the pen firmly down, then press the plum activator button. You'll hear a click. Keep holding until the yellow marker fills the window and stops moving. This can take up to 15 seconds.
- Remove and disposeLift the pen straight off. A drop of liquid is normal. Press gauze on the site (don't rub it), then put the pen in an FDA-cleared sharps container, not the household trash.
Current Humira pens use a citrate-free, high-concentration formula: 40 mg in 0.4 mL instead of the original 0.8 mL. That means half the liquid and no citrate buffer, which was a known source of injection-site stinging. The more concentrated liquid is also slightly thicker, which is why the injection takes a few seconds. If you switch to a biosimilar, check whether it's also citrate-free and high-concentration. Not all of them are.
Humira side effects
The most common side effects (more than 10% of patients) are injection site reactions, upper respiratory infections, sinusitis, headache and rash. The chart shows how often each happened on Humira compared with placebo in the pooled rheumatoid arthritis trials.
Source: HUMIRA FDA prescribing information, section 6.1 and Table 1. In RA trials, 7% of Humira patients stopped because of side effects, compared with 4% on placebo.
A few side effects people often search for:
Weight gain, tiredness, hair loss
- Weight gain
- Not a listed common side effect. Some TNF-blocker studies found modest gain, probably because inflammation that was burning energy is now controlled.
- Fatigue
- Not a top trial side effect. New, unusual tiredness can signal infection or low blood counts, so report it.
- Hair loss
- Alopecia is listed among reports received after approval. How often it happens is unknown.
Worth reporting promptly
- New or worse psoriasis
- TNF blockers can trigger psoriasis, including pustular and palm/sole types. This paradoxical effect is listed on the label.
- Liver enzymes
- ALT at 3× the normal limit or higher occurred in 3.5% of patients (1.5% on control), mostly those also taking methotrexate or NSAIDs.
- Lupus-like symptoms
- Rare. The label says to stop Humira if a lupus-like syndrome develops.
Boxed warning and when to call your doctor
Serious infections. Humira raises the risk of infections serious enough to cause hospitalization or death, including tuberculosis (often reactivated latent TB), invasive fungal infections such as histoplasmosis, and bacterial infections including sepsis. Most patients who developed these were also taking methotrexate or corticosteroids. In trials, serious infections occurred at 4.3 per 100 patient-years on Humira vs. 2.9 on control.
Malignancy. Lymphoma and other cancers, some fatal, have been reported in children and teens on TNF blockers. Rare cases of hepatosplenic T-cell lymphoma, an aggressive and usually fatal lymphoma, occurred mostly in adolescent and young adult males with Crohn's disease or UC who were also taking azathioprine or 6-mercaptopurine.
For most adults this risk is managed with testing before starting, monitoring during treatment, and acting fast on warning signs:
Usually fine
- Mild redness, itching or swelling at the injection site that fades within a few days
- A mild cold without fever
- A mild headache
Within a day or two
- Fever, cough, burning when you urinate, or a skin infection
- Scheduled surgery or dental work (your doctor may time doses around it)
- New psoriasis patches, patchy hair loss, or unusual tiredness
- A joint rash plus sun sensitivity (possible lupus-like reaction)
Get help now
- High fever, chills, or feeling very unwell (possible sepsis)
- Hives, swelling of the face or lips, or trouble breathing
- Yellow skin or eyes, or dark urine
- Sudden vision change, numbness or weakness
- Shortness of breath with ankle swelling (heart failure)
Before you start: tests, vaccines, pregnancy
- TB test. A skin or blood test for latent tuberculosis is required before the first dose. If it's positive, TB treatment starts first. You'll still be watched for TB during treatment, even with a negative test.
- Hepatitis B test. Humira can reactivate hepatitis B in carriers. Carriers are monitored during treatment and for several months after stopping.
- Get vaccines up to date first. Live vaccines (such as MMR, varicella, yellow fever, and the nasal flu spray) must be avoided while on Humira. Inactivated vaccines such as the flu shot, COVID-19, pneumococcal and Shingrix are generally fine. Our pharmacists give many of these. See immunizations.
- Tell your prescriber about heart failure, multiple sclerosis or other nerve disorders, cancer history, recurring infections, or time spent in areas where fungal infections such as histoplasmosis (Ohio and Mississippi River valleys) are common.
- Pregnancy. Registry data show no pattern of birth defects (10% vs. 7.5% in a comparable unexposed group, which the registry's design can't reliably attribute to the drug). Adalimumab crosses the placenta late in pregnancy, so an exposed baby shouldn't get live vaccines, such as rotavirus, without the pediatrician's review.
Drug interactions and alcohol
| Combination | What can happen |
|---|---|
| Other biologics: abatacept (Orencia), anakinra (Kineret), other TNF blockers | Higher serious-infection risk with no added benefit. Not recommended together. |
| Live vaccines | Avoid them while on Humira. The vaccine virus could cause infection. |
| Azathioprine or 6-mercaptopurine (in Crohn's/UC) | Linked to the rare hepatosplenic T-cell lymphoma cases in young males |
| Methotrexate | Commonly combined for RA and PsA. No dose change needed. It also cuts antibodies against Humira: in RA trials, 1% of patients on methotrexate developed them vs. 12% on Humira alone. |
| Narrow-range drugs processed by the liver: warfarin, cyclosporine, theophylline | Controlling inflammation can change how these drugs are processed. Monitor levels when Humira is started or stopped. |
| Alcohol | No direct interaction listed. The concern is the liver, especially if you also take methotrexate. |
Generic Humira? The 10 FDA-approved biosimilars
"Humira generic" is one of the most-searched questions about this drug. Biologics can't be copied exactly the way pills can, so instead of generics they get biosimilars: products the FDA has confirmed have no clinically meaningful differences in safety, purity or effectiveness. US biosimilars began launching in 2023, after Humira's main patents expired.
| Biosimilar | Official name | Company | FDA approved | Interchangeable* |
|---|---|---|---|---|
| Amjevita | adalimumab-atto | Amgen | Sep 2016 | Yes |
| Cyltezo | adalimumab-adbm | Boehringer Ingelheim | Aug 2017 | Yes |
| Hyrimoz | adalimumab-adaz | Sandoz | Oct 2018 | Yes |
| Hadlima | adalimumab-bwwd | Samsung Bioepis / Organon | Jul 2019 | Yes |
| Abrilada | adalimumab-afzb | Pfizer | Nov 2019 | Yes |
| Hulio | adalimumab-fkjp | Biocon Biologics | Jul 2020 | Yes |
| Yusimry | adalimumab-aqvh | Coherus (developer) | Dec 2021 | Not designated |
| Idacio | adalimumab-aacf | Fresenius Kabi | Dec 2022 | Not designated |
| Yuflyma | adalimumab-aaty | Celltrion | May 2023 | Yes |
| Simlandi | adalimumab-ryvk | Alvotech / Teva | Feb 2024 | Yes |
The biggest savings come from unbranded biosimilars. The same product is sold without a brand name at a much lower list price. This is what US pharmacies actually pay per pen, from CMS's national drug acquisition cost survey:
Source: CMS NADAC, data.medicaid.gov, September 2026 survey. Adalimumab-adaz is priced per mL ($1,587.82/mL × 0.4 mL). Adalimumab-aaty ranges $490–501 by package. NADAC is the pharmacy's cost, not your out-of-pocket price.
At wholesale, one brand-name Humira pen costs about the same as five to seven unbranded biosimilar pens.
Humira vs. Skyrizi, Rinvoq, Enbrel and other alternatives
If Humira stops working, isn't covered, or never worked well enough, several other drug classes treat the same conditions. They block different parts of the immune system:
| Drug | How it works | How it's taken | Main overlap with Humira |
|---|---|---|---|
| Humira (adalimumab) | TNF-α blocker (antibody) | Injection, usually every 2 weeks | — |
| Enbrel (etanercept) | TNF blocker (receptor fusion protein) | Injection, weekly | RA, PsA, AS, psoriasis, JIA. Not approved for Crohn's or UC. |
| Skyrizi (risankizumab) | IL-23 inhibitor | Injection every 12 weeks after starter doses (psoriasis, PsA). IV starter doses for Crohn's and UC. | Psoriasis, PsA, Crohn's, UC |
| Rinvoq (upadacitinib) | JAK inhibitor | Pill, once daily | RA, PsA, AS, Crohn's, UC. Usually after a TNF blocker. Has its own boxed warning. |
| Cosentyx (secukinumab) | IL-17A inhibitor | Injection, usually every 4 weeks after starter doses | Psoriasis, PsA, AS, HS |
| Stelara (ustekinumab) and its biosimilars | IL-12/23 inhibitor | Injection every 8–12 weeks | Psoriasis, PsA, Crohn's, UC |
Skyrizi vs. Humira for psoriasis. The two work differently. Humira blocks TNF-α, which sits early in the inflammatory chain. Skyrizi blocks IL-23, which drives the specific immune cells (Th17) behind psoriasis plaques. In the head-to-head IMMvent trial, 72% of patients on risankizumab reached 90% skin clearance (PASI 90) at week 16, compared with 47% on adalimumab. Humira's advantages are its long safety record, its broad range of approved conditions (including joint disease that newer skin drugs don't all cover), and the low price of biosimilars. Many insurers still require a TNF blocker first.
Humira price, copay card and savings
Humira's list price is about $6,900 for two pens, which is one month for most adults. Very few people pay that. What you pay depends on how you're covered:
Copay card
- Humira Complete Savings Card
- Eligible commercially insured patients may pay as little as $5 a month. An annual maximum applies, and some copay accumulator or maximizer plans reduce the benefit.
- Biosimilars
- Most biosimilar makers offer their own copay programs, often with similar terms.
- Prior authorization
- Almost always required. Our specialty team handles it.
$2,100 yearly cap
- Out-of-pocket maximum (2026)
- $2,100 a year for all covered Part D drugs combined, set by the Inflation Reduction Act
- Spread the cost
- The Medicare Prescription Payment Plan turns that into monthly payments
- Copay cards
- Not allowed with Medicare. Many plans prefer a specific biosimilar.
- Uninsured or underinsured? Ask about myAbbVie Assist, AbbVie's patient assistance program, which provides Humira free to people who meet income and coverage criteria. Many biosimilar makers run similar programs.
- Paying cash? An unbranded biosimilar is almost always the cheapest route. Some manufacturers have offered low cash prices through discount platforms. For example, Boehringer Ingelheim announced adalimumab-adbm at $550 per two-pack through GoodRx in 2024. Ask us for a current quote before you assume brand pricing.
- Humira coupons from random websites that promise brand Humira "without a prescription" or at pill-like prices are red flags. Genuine savings come from the manufacturer, your insurer, or a licensed pharmacy.
See our patient assistance programs page for more on copay cards and foundation grants.
How to buy Humira with a prescription
Humira is prescription-only and almost always needs prior authorization, so getting it takes a few more steps than a routine refill. Here's how it works at Arrow Pharmacy:
- Get a prescription from your specialistThis is usually a rheumatologist, gastroenterologist or dermatologist, after your TB and hepatitis B tests. The prescriber can send it to us electronically, or you can transfer an existing prescription.
- We check your coverageWe confirm whether your plan covers brand Humira or a specific biosimilar. We also check whether your plan requires a designated specialty pharmacy. Some do, and we'll tell you honestly if that's the case.
- We handle the prior authorizationOur Specialty Care team gathers your chart notes from the prescriber, submits the request, and follows up with the insurer.
- We apply the savingsThat means a manufacturer copay card if you're commercially insured, or the Medicare payment plan or patient assistance if you're not.
- Pick up or get it delivered coldPick it up at our Hartford pharmacy, or ask about next-day delivery. We'll show you how to use the pen or syringe on your first fill.
Call us at (860) 522-9289. A pharmacist, not a call center, will check your coverage, compare brand Humira with the biosimilars your plan prefers, and start the prior authorization.
No active shortage reported — Shortage records exist for this drug historically, but none are currently marked active.
FDA openFDA — Updated 2026-09-29National Average Drug Acquisition Cost (NADAC): $3,367.415 per pen (HUMIRA(CF) PEN 40 MG/0.4 ML). This is the average price pharmacies pay wholesalers — not your out-of-pocket cost — published by CMS for pricing transparency.
CMS NADAC — Updated 2026-09-29Humira (Adalimumab) Prices in the USA
| Dosage | Brand-name avg. price | Generic avg. price |
|---|---|---|
| Pen 40 mg/0.4 mL, carton of 2 (a 28-day supply at every-other-week dosing) | $6,900–7,700 (Humira) | $1,000–2,000 (unbranded biosimilar adalimumab) |
| Pen 40 mg/0.4 mL, 4 pens (28 days at weekly dosing — HS, some RA) | $13,800–15,400 (Humira) | $2,000–4,000 (unbranded biosimilar adalimumab) |
| Pen 80 mg/0.8 mL, carton of 2 | $13,800–15,400 (Humira) | Varies by product — ask us for a quote |
Frequently asked questions
What is Humira used for?
Humira (adalimumab) is FDA-approved for nine conditions: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (age 2+), psoriatic arthritis, ankylosing spondylitis, Crohn's disease (age 6+), ulcerative colitis (age 5+), moderate-to-severe plaque psoriasis, hidradenitis suppurativa (age 12+), and non-infectious uveitis (age 2+). What they have in common is an overactive immune response driven partly by a protein called TNF-alpha, which Humira blocks. It is not a painkiller and not a cure — it calms the underlying inflammation so the disease does less damage over time.
Is there a generic Humira?
Not a generic in the traditional sense, because Humira is a biologic — a large protein made in living cells — and exact copies aren't possible. Instead there are biosimilars: versions the FDA has confirmed have no clinically meaningful differences in safety or effectiveness. Ten adalimumab biosimilars are FDA-approved, including Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada, Hulio, Yusimry, Idacio, Yuflyma and Simlandi. Several are also sold unbranded as simply "adalimumab-xxxx" (for example adalimumab-adbm or adalimumab-aaty), usually at the lowest price. Most have an FDA "interchangeable" designation for at least some strengths and devices, which lets a pharmacist substitute them for Humira where state law allows.
What are the worst side effects of Humira?
The most serious risks are the two in Humira's boxed warning: serious infections (including tuberculosis, invasive fungal infections and sepsis) that can lead to hospitalization or death, and a small increased risk of some cancers, particularly lymphoma in children and adolescents and a rare, aggressive lymphoma (hepatosplenic T-cell lymphoma) mostly seen in young men with Crohn's disease or ulcerative colitis who also took azathioprine or 6-mercaptopurine. Less common but serious: hepatitis B reactivation, new or worsening heart failure, nerve problems such as multiple sclerosis-like demyelination, low blood counts, lupus-like syndrome, and severe allergic reactions. In clinical trials serious infections occurred at 4.3 per 100 patient-years on Humira versus 2.9 on control.
How long does it take for Humira to work?
Some people notice improvement within the first 2 weeks — the label reports improvement in ankylosing spondylitis first seen at week 2 — but most of the benefit builds over about 3 months. Clinical trials judged the main result at week 4 for Crohn's induction, week 8 for ulcerative colitis, week 12 for hidradenitis suppurativa, ankylosing spondylitis and rheumatoid arthritis, and week 16 for plaque psoriasis. For ulcerative colitis specifically, the label says to stop Humira if there is no clinical remission by week 8 (day 57).
Does Humira cause weight gain?
Weight gain is not listed among Humira's common side effects in the FDA label. That said, studies of TNF blockers as a class have observed modest weight gain in some patients, which is thought to reflect active inflammation being brought under control (chronic inflammation raises energy use and can suppress appetite) rather than a direct drug effect. If you notice significant weight change after starting Humira, mention it to your prescriber so other causes — including steroid use, which often overlaps with starting a biologic — can be ruled out.
Can Humira cause hair loss?
Hair loss (alopecia) appears in Humira's label among side effects reported after approval. Because these reports are voluntary, the FDA says it is not possible to reliably estimate how often it happens or prove Humira caused it. Paradoxically, TNF blockers can also trigger new or worsening psoriasis, including on the scalp, which can itself lead to hair shedding. Tell your prescriber about new patchy hair loss or scalp plaques rather than stopping on your own.
Is Humira an immunosuppressant?
Yes. Humira is a biologic immunosuppressant in the TNF-blocker class — it selectively blocks one inflammatory signal (TNF-alpha) rather than suppressing the whole immune system the way high-dose steroids do. That selectivity is why it's effective, and also why infections are its main risk: TNF is part of how your body contains infections like tuberculosis. You will be tested for latent TB before starting.
How long can Humira be out of the fridge?
Up to 14 days at room temperature, up to 77°F (25°C), protected from light in its original carton — for example while traveling. Write the date you took it out on the carton, and throw it away if it hasn't been used within 14 days. Never freeze Humira, and never use it if it has been frozen, even after thawing. Before a normal injection, leave the pen out for 15 to 30 minutes so the medicine reaches room temperature — do not warm it in a microwave or hot water.
What if I miss a dose of Humira, or I'm a few days late?
Per the Humira Medication Guide: inject the missed dose as soon as you remember, then take your next dose at your regular scheduled time — that puts you back on schedule. Do not double up. If you are unsure which day to use, call your prescriber or pharmacist.
Can you drink alcohol on Humira?
Humira's label lists no direct interaction with alcohol. The bigger issue is usually methotrexate, which many patients take alongside Humira for rheumatoid or psoriatic arthritis — methotrexate and alcohol together raise the risk of liver damage, and liver enzyme elevations were also seen in Humira trials (mostly in patients also taking methotrexate or NSAIDs). Ask your prescriber what limit is safe for your specific regimen.
Can you take Humira while pregnant?
Sometimes, with your specialist's guidance. A pregnancy registry found major birth defects in 10% of babies exposed to adalimumab in the first trimester versus 7.5% in a comparable unexposed group, with no pattern of specific defects — a difference the FDA says the registry's design can't reliably attribute to the drug. Uncontrolled rheumatoid arthritis or inflammatory bowel disease itself raises the risk of preterm birth and low birth weight. Adalimumab crosses the placenta in the third trimester, so a baby exposed in the womb should not receive live vaccines (such as rotavirus) without the pediatrician weighing the risk.
Does Medicare cover Humira?
Most Medicare Part D and Medicare Advantage drug plans cover adalimumab in some form, usually with prior authorization and often preferring a specific biosimilar over brand Humira. Manufacturer copay cards cannot be used with Medicare. The important 2026 protection: Part D caps your total yearly out-of-pocket cost for covered drugs at $2,100, and the Medicare Prescription Payment Plan can spread that cost into monthly payments. We can check your plan's formulary and whether Humira or a biosimilar is the covered option.
How much is Humira without insurance?
Brand Humira's cash price is roughly $6,900–7,700 for a carton of two 40 mg pens (a 28-day supply for most adults), and pharmacies themselves pay about $3,367 per pen at wholesale according to CMS NADAC data. Unbranded biosimilars are dramatically cheaper — pharmacies pay roughly $490–640 per pen for adalimumab-aaty and adalimumab-adbm — and some manufacturers run cash-price programs below that (Boehringer Ingelheim announced $550 per two-pack of adalimumab-adbm through GoodRx in 2024). If you are uninsured or underinsured, also ask about myAbbVie Assist, AbbVie's patient assistance program, which can provide Humira at no cost to people who qualify.
Can I switch from Humira to a biosimilar?
Yes — switching is common, often because an insurer moves Humira off its formulary in favor of a biosimilar. FDA approval requires a biosimilar to have no clinically meaningful differences from Humira. Before switching, check two practical details with your pharmacist: the concentration (high-concentration 100 mg/mL products deliver 40 mg in 0.4 mL, low-concentration ones in 0.8 mL) and whether the product is citrate-free, since both can affect how the injection feels. The device (pen shape, button vs. push-on-skin) also differs, so ask for a quick demonstration of the new one.
Is Humira a controlled substance?
No. Adalimumab is not on any DEA controlled-substance schedule. It is prescription-only, and most insurers also require prior authorization because of its cost and because guidelines usually reserve it for moderate-to-severe disease.
Sources
- HUMIRA (adalimumab) injection — FDA-approved prescribing information, Medication Guide and Instructions for Use (revised 12/2025) — U.S. National Library of Medicine (DailyMed) / U.S. FDA
- Biosimilar Product Information — FDA-approved biosimilar products — U.S. Food and Drug Administration
- Purple Book: Database of Licensed Biological Products (interchangeability status by presentation) — U.S. Food and Drug Administration
- Biosimilar and Interchangeable Biologics: More Treatment Choices — U.S. Food and Drug Administration
- NADAC (National Average Drug Acquisition Cost) — HUMIRA(CF) PEN 40 MG/0.4 ML and unbranded adalimumab biosimilar pens — CMS
- openFDA Drug Shortages — U.S. FDA
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial — The Lancet (2019), via PubMed
- Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm — Boehringer Ingelheim (2024)
- Final CY 2026 Part D Redesign Program Instructions ($2,100 out-of-pocket threshold) — Centers for Medicare & Medicaid Services
- Patient Savings Programs (Humira Complete Savings Card, myAbbVie Assist) — AbbVie